Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.02 USD | +1.73% | +3.34% | -11.01% |
18/04 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
17/04 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.01% | 4.67B | |
+23.55% | 48.09B | |
+46.90% | 40.62B | |
-2.64% | 40.43B | |
-6.20% | 28.36B | |
+8.43% | 24.89B | |
-20.05% | 19.01B | |
+28.93% | 12.09B | |
-0.17% | 11.88B | |
-0.93% | 11.8B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics : Chardan Adjusts Price Target on CRISPR Therapeutics to $171 From $175, Maintains Buy Rating